NasdaqGM:HROWPharmaceuticals
Is It Too Late To Consider Harrow (HROW) After Its Strong Multi Year Rally
If you are wondering whether Harrow's share price still makes sense after its recent run, or if you are looking at something that is already priced for perfection, this article is for you.
Over the last week Harrow returned 10.8%, after a 13.9% decline over the past month, with a 5.4% decline year to date, a 52.8% return over 1 year, and a very large 3-year gain of more than 7x.
Recent coverage has focused on Harrow's position in the pharmaceuticals space and investor interest in its share...